Cite
HARVARD Citation
Ständer, S. et al. (2022). High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. Journal of the European Academy of Dermatology and Venereology. pp. 1308-1317. [Online].